Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Aura Biosciences, Inc. (NASDAQ: AURA), a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. These regulatory documents provide detailed insight into AURA’s financial condition, clinical development plans, governance, and capital markets activity.
Among the most frequently referenced filings are Aura’s Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, research and development focus on bel-sar (AU-011), and operating expenses tied to its global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, additional ocular oncology programs, and non-muscle invasive bladder cancer. Investors can also review Form 8-K current reports, such as those filed on dates when Aura announces quarterly results or updates its corporate presentation, to see how the company communicates material events and financial updates.
For users interested in ownership and governance, SEC filings provide information on matters submitted to stockholder votes, including director elections and auditor ratification, as illustrated by Aura’s Form 8-K reporting results of its annual meeting of stockholders. Registration statements and prospectus supplements related to public offerings of common stock and warrants detail how the company raises capital to fund its clinical programs and general corporate purposes.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly understand clinical priorities, cash runway disclosures, and risk factor discussions without reading every page. Real-time updates from EDGAR ensure new AURA filings appear promptly, while structured access to forms such as 10-K, 10-Q, 8-K, and registration statements allows investors to navigate Aura Biosciences’ regulatory history efficiently.
Aura Biosciences reports amended Schedule 13G/A showing Advent-affiliated entities may beneficially own an aggregate
Dr. Rajesh Parekh, a general partner of Advent, is reported with options to purchase 48,000 shares and may be deemed to beneficially own 2,071,857 shares (
Aura Biosciences reports a proposed sale of 22,619 shares of common stock. The shares are issuable under a Restricted Stock Unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan on
Aura Biosciences reported a Form 144 notice for a proposed sale of common stock. The filing lists 15,890 shares with Morgan Stanley Smith Barney LLC as the broker and a filing date of 02/17/2026. The excerpt also shows restricted stock unit awards of 7,129 (granted 02/01/2024) and 22,619 (granted 02/03/2025).
Aura Biosciences submitted a Form 144 notice relating to Common Stock transactions through Morgan Stanley Smith Barney LLC. The filing records a sale of
Amy Elazzouzi reported a sale of 1,581 shares of Common Stock on
The broker listed is Morgan Stanley Smith Barney LLC at the address shown, and the filing references Nasdaq with an apparent filing activity date of
Aura Biosciences filed a Form 144 reporting a proposed sale of 47,648 shares of Common Stock. The filing lists Morgan Stanley Smith Barney LLC as the broker and Nasdaq as the market. The filing also shows prior insider activity: Elisabet de los Pinos sold 16,928 shares on
Kilroy Conor reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 12,079 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 167,234 shares.
Plavsic Mark reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 15,890 shares at a weighted average price of $5.05 per share. Following the reported transactions, holdings were 181,397 shares.
Hopkins Janet Jill reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 20,401 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 232,284 shares.
Elazzouzi Amy reported open-market sale transactions in a Form 4 filing for AURA. The filing lists transactions totaling 8,549 shares at a weighted average price of $5.06 per share. Following the reported transactions, holdings were 75,532 shares.